September 9, 2019– Congress is back in town this week after the end of its August recess, and lawmakers are gearing up for a busy fall with a major focus on how to slow down ever-increasing drug prices. The cost of prescription drugs is on the minds of members from both parties in Congress as well as members of the Trump administration. Before they left town, two Senate … [Read more...]
Pillars of Care: Five Important Ways That Medicaid and 340B Are Alike
by Maureen Testoni June 20, 2019– Web headlines such as “10 Things You Missed in the Game of Thrones Finale!’” are the epitome of clickbait, but they are effective in getting people’s attention. So let’s try this: Can you name the five important ways that Medicaid and the 340B drug pricing program are alike? The answers might surprise you! Even most casual observers know … [Read more...]
Drug companies answer scrutiny with more lobbying dollars
May 2, 2019— With its pricing practices under a congressional microscope, the pharmaceutical industry’s top trade group spent nearly $10 million on lobbying expenditures in the first three months of this year. That figure is on top of additional millions spent by some of the individual companies that have received the most attention recently in the drug pricing … [Read more...]
Death, Taxes…and Drug Price Increases
July 6, 2018—There’s new evidence that pharmaceutical manufacturers have not gotten the message that the Trump administration and the American public want an end to rising drug prices. Research documenting a host of drug price increases in June and July above the rate of inflation could complicate the Trump administration’s advocacy for its drug pricing blueprint, which … [Read more...]
Patients, Consumers, and Providers Urge Congress to Support 340B
May 15, 2018—A broad coalition of patient and consumer advocacy groups urged congressional leaders yesterday to join them “in supporting, not weakening, the 340B program.” The 61 groups made the appeal as Congress debates a variety of proposals to alter the program and on the eve of a Senate committee hearing this morning on the drug discount program. In their May 14 letter, … [Read more...]
House Panel Issues 340B Report; 340B Health Both Appreciative and Concerned
January 10, 2018—The full House Energy & Commerce Committee released a report this afternoon calling on Congress to clarify the 340B program’s intent, give the Health Resources and Services Administration (HRSA) more regulatory authority over the program, increase reporting requirements for hospitals, and revise hospital eligibility requirements. 340B Health, which … [Read more...]
Bipartisan Senate Group Asks Leaders to Help Block 340B Hospital Cuts
December 6, 2017—Efforts to block impending cuts to Medicare Part B payments to 340B hospitals gained momentum this week as a bipartisan group of six U.S. senators urged party leaders to enact legislation stopping the cuts before the end of December. The Dec. 5 letter from Sens. John Thune (R-S.D.), Rob Portman (R-Ohio), Shelley Moore Capito (R-W.Va.), Bill Nelson (D-Fla.), … [Read more...]